Clearbridge's device can detect CTCs without antibodies

06/5/2013 |

Clearbridge BioMedics has introduced the ClearCell FX technology, which can detect circulating tumor cells without the need for antibodies or other labeling techniques, this article says. The system, co-developed with Cambridge Consultants, incorporates a tiny device called the CTChip FR that employs fluid dynamics to isolate CTCs from other cells in blood for further analysis.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ